感染症体外診断薬市場：製品、技術、適応症、エンドユーザー別-2024-2030年の世界予測

感染症体外診断薬市場規模は2023年に490億6,000万米ドルと推定され、2024年には525億1,000万米ドルに達し、CAGR 7.22％で2030年には799億5,000万米ドルに達すると予測されます。

感染症体外診断薬市場は、血液、尿、咽頭ぬぐい液などのヒト試料から感染症を検出・同定するための装置、消耗品、サービスで構成されます。これらの診断薬の用途は、ヒト免疫不全ウイルス（HIV）、肝炎、結核、性感染症（STI）、呼吸器感染症など多岐にわたる。これらの検査は、感染症の早期発見、疾病サーベイランス、疫学、管理に極めて重要です。感染症IVD市場の成長は、世界の感染症流行の増加、早期発見と予防の重要性に対する認識と教育の高まり、ヘルスケア支出の増加とヘルスケアインフラへの投資といった要因の影響を受けています。しかし、厳しい規制環境、インフラや訓練を受けた人材の不足、先端技術の高コストが市場成長の大きな障壁となっています。さらに、迅速な現場診断のためのポイントオブケア検査キットの開発や、診断精度の向上と予測分析のための人工知能と機械学習アルゴリズムの統合は、感染症体外診断薬に大きな成長機会を提供します。

製品感染性病原体検査用の高度な試薬に対する需要の高まり

感染症診断には、臨床サンプル中の病原体の存在を検出するために設計された高度で専門的な機器が必要です。これらの機器は、単純なポイントオブケア検査キットから、PCR装置、イムノアッセイ分析装置、次世代シークエンサーなどの複雑な検査機器まで様々です。ヘルスケアの現場によって機器の必要性は異なり、基準検査室では効率性と自動化のために高スループットシステムが好まれる一方、ポイントオブケア現場では携帯可能で使い勝手の良い機器が求められます。試薬は感染症診断に不可欠な消耗品であり、病原体特異的マーカーの存在を検出するための検査に使用される化学物質や生物学的物質で構成されます。試薬には、プライマー、プローブ、抗体、酵素など、検査に必要なものが含まれます。試薬の必要性は、実施される検査の量と検査可能な病原体の多様性によって支えられています。そのため、検査施設では、複数の検査機器プラットフォームに対応する様々な試薬を提供できるベンダーが好まれることが多いです。感染症診断のソフトウェア分野には、データ解析、解釈ソフトウェア、情報管理システムなどが含まれ、診断の業務効率化に不可欠です。ソフトウェアの好みは、ユーザーフレンドリーなインターフェース、堅牢なデータ管理機能、他の病院システムとの相互運用性、HIPAAなどの規制基準への準拠に基づいています。

テクノロジー：HIV感染や肝炎感染など、ウイルス量を迅速に検出・定量化する分子診断技術の採用拡大

免疫化学（イムノアッセイ）は感染症診断における重要な技術であり、免疫反応（抗体、抗原）を利用してサンプル中の特定のバイオマーカーを検出・定量します。これにはELISA（酵素結合免疫吸着測定法）、ラテラルフローアッセイ、ウェスタンブロッティングなどの検査が含まれます。微生物学は、感染症を特定するための基本的な方法であり、多くの場合、サンプルを採取して生化学的および表現型分析を用いて病原体を分離・同定します。微生物学は薬剤耐性試験や感染症の疫学を理解するために不可欠です。病原体の抗生物質感受性に関する情報が必要な場合は、標的治療の指針となります。分子診断学では、核酸を分析して感染因子を高い感度と特異性で同定します。一般的な技術には、ポリメラーゼ連鎖反応、逆転写PCR、次世代シーケンサーなどがあります。

地域別インサイト

南北アメリカは、先進的なヘルスケアインフラ、感染症の高い流行率、有力企業の強い存在感により、感染症体外診断薬市場の大部分を占めています。最近の動向としては、分子診断（MDx）、Point-of-Care（PoC）検査の採用、個別化医療への投資の増加などが挙げられます。EU諸国は多様なヘルスケア制度と規制を有しているが、全体として高品質の体外診断薬に対する強い需要を示しています。EUの顧客は検査の精度と信頼性を重視し、さらにEUの厳しい規制を遵守する必要があります。中東・アフリカ地域は、発展度合いの異なる様々な市場を包含しています。中東諸国では、最新の体外診断用医薬品を含む最先端のヘルスケアソリューションに対する需要が大きいです。湾岸協力会議（GCC）諸国では、ヘルスケア・インフラへの投資が顕著です。一方、アフリカ市場では、感染症の蔓延やヘルスケアへのアクセス制限といった課題から、費用対効果の高い堅牢な検査が求められています。国際的なイニシアチブが投資と技術革新を推進することが多く、診断薬へのアクセス拡大と現地専門家の育成に重点が置かれています。

アジア太平洋地域は感染症体外診断薬市場において急速に成長しています。中国の膨大な人口と医療費の増加が市場成長の原動力であり、ヘルスケア・インフラの改善に対する政府の強力な支援があります。先進技術を有する日本は、ハイエンドの自動診断ソリューションに注力しており、診断技術に関する重要な特許を有するイノベーションの中心地です。インド市場は、意識の高まりと手頃な価格により急成長しています。予防検診と診断へのアクセスは、アジア太平洋地域の顧客の購買行動において極めて重要となっています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは感染症体外診断薬市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、感染症体外診断薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.感染症体外診断薬市場の市場規模および予測は？

2.感染症体外診断薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.感染症体外診断薬市場の技術動向と規制枠組みは？

4.感染症体外診断薬市場における主要ベンダーの市場シェアは？

5.感染症体外診断薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 感染症の蔓延と定期的な流行の増加
    • 感染症の診断における迅速検査キットの導入増加
    • ウイルス性疾患の抑制に向けた政府の取り組みの実施
  • 抑制要因
    • 感染症体外診断用製品のリコール
  • 機会
    • ゲノミクスとプロテオミクスの進歩
    • 新しいIVD製品の発売に向けて研究開発への投資を増加
  • 課題
    • 感染症体外診断薬キットのアクセス制限
• 市場セグメンテーション分析
  • 製品：感染性病原体の検査のための高度な試薬の需要の高まり
  • 技術：HIVや肝炎感染などのウイルス量を迅速に検出し定量化するための分子診断技術の採用拡大
• 市場動向分析
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析
• 顧客のカスタマイズ

第6章 感染症体外診断薬市場：製品別

• 機器
• 試薬
• ソフトウェア

第7章 感染症体外診断薬市場：技術別

• 免疫化学
• 微生物学
• 分子診断

第8章 感染症体外診断薬市場適応症別

• カンジダ症
• クラミジア
• クロストリジウム・ディフィシル
• クリエイティブ
• 胃腸炎
• 淋病
• 肝炎
• HIV
• HPV
• MRSA
• 呼吸器ウイルス
• 連鎖球菌
• 結核と薬剤耐性結核
• ＶＲＥ

第9章 感染症体外診断薬市場：エンドユーザー別

• 学術調査機関
• 診断検査室
• 病院・クリニック

第10章 南北アメリカの感染症体外診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の感染症体外診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの感染症体外診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • ロシュ、分子診断における臨床ニーズの向上と公衆衛生の課題への対応を目指して次世代Qpcrシステムを発表
  • バイオケアメディカル、信頼性、精度、一貫性のある熱誘導エピトープ回収（HIER）を実現する新しいIVD抗原回収チャンバーARCの発売を発表
  • 免疫組織化学用の新しい試薬ソリューション「Optimer-Fc」の発売
  • DxLabはトースターサイズの箱で、感染症や有害病原体の検査室品質の検出を実現します

第14章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET DYNAMICS
• FIGURE 7. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 18. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 24. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CRE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CRE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GASTROENTERITIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GASTROENTERITIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HIV, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HIV, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HPV, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HPV, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MRSA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MRSA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY RESPIRATORY VIRUS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY RESPIRATORY VIRUS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STREPTOCOCCUS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STREPTOCOCCUS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TB AND DRUG-RESISTANT TB, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TB AND DRUG-RESISTANT TB, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VRE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VRE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 59. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 60. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 61. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 62. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 63. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 64. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 65. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 66. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 67. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 68. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 69. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 70. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 71. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 72. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 73. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 74. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 75. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 76. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 77. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 78. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 79. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 80. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 81. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 82. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 83. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 84. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 85. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 86. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 87. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 88. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 89. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 90. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 91. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 92. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 93. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 94. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 95. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 96. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 97. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 98. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 99. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 100. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 101. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 102. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 103. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 104. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 105. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 106. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 107. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 108. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 109. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 110. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 111. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 112. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 113. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 114. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 116. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 117. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 118. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 119. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 120. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 121. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 122. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 123. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 124. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 125. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 126. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 127. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 128. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 129. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 130. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 131. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 132. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 133. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 134. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 135. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 136. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 137. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 138. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 139. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 140. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 141. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 142. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 143. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 144. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 145. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 146. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 147. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 148. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 149. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 150. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 151. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 152. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 153. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 154. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 155. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 156. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 157. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 158. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 159. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 160. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 161. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 162. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 163. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 164. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 165. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 166. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 167. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 168. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 169. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 170. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 171. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 172. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 173. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 174. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 175. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 176. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 177. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 178. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 179. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 180. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 181. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 182. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 183. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 184. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 185. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 186. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 187. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 188. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 189. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 190. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 191. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 192. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 193. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 194. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 195. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 196. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 197. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 198. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 199. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 200. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 201. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 202. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 203. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 204. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 205. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 206. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 207. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 208. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 209. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 210. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 211. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 212. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 213. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 214. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 215. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 216. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 217. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 218. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 222. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 223. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 224. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 225. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 226. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 227. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 228. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 229. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 230. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 231. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 232. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 233. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 234. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 235. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 236. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 237. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 238. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 239. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 240. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 241. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 242. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 243. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 244. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 245. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 246. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 247. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 248. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 249. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 250. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 251. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 252. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 253. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 254. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 255. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 256. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 257. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 258. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 259. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 260. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 261. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 262. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 263. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 264. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 265. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 266. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 267. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 268. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 269. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 270. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 271. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 272. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 273. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 274. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 275. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 276. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 277. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 278. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 279. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 280. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 281. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 282. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 283. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 284. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 285. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 286. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 287. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 288. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 289. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)

TABLE 290

[189 Pages Report] The Infectious Diseases In-Vitro Diagnostics Market size was estimated at USD 49.06 billion in 2023 and expected to reach USD 52.51 billion in 2024, at a CAGR 7.22% to reach USD 79.95 billion by 2030.

The infectious diseases in-vitro diagnostics market comprises devices, consumables, and services used to detect and identify infectious diseases in human samples, such as blood, urine, throat swabs, and others. The applications of these diagnostics encompass a wide range of diseases, such as Human Immunodeficiency Virus (HIV), Hepatitis, Tuberculosis (TB), Sexually Transmitted Infections (STIs), Respiratory Infections, and others. These tests are crucial for early detection, disease surveillance, epidemiology, and management of infections. The growth of the infectious diseases IVD market is influenced by factors such as the increased prevalence of infectious diseases globally, growing awareness and education about the importance of early detection and prevention, and rising healthcare expenditures and investments in healthcare infrastructure. However, stringent regulatory environments, lack of infrastructure and trained personnel, and high cost of advanced technologies are significant barriers to the market growth. Furthermore, developing point-of-care testing kits for rapid and on-site diagnosis and integrating artificial intelligence and machine learning algorithms to improve diagnostic accuracy and predictive analytics offer significant growth opportunities for infectious diseases in-vitro diagnostics.

Product: Rising demand for advanced reagents for testing infectious pathogens

Infectious disease diagnostics require sophisticated and specialized instruments designed to detect the presence of pathogens in clinical samples. These instruments vary from simple point-of-care testing kits to complex laboratory equipment, including PCR machines, immunoassay analyzers, and next-generation sequencers. The need for instruments can vary by healthcare setting; high-throughput systems are preferred in reference laboratories for their efficiency and automation, while point-of-care settings demand portable and user-friendly instruments. Reagents are essential consumables in infectious disease diagnostics, consisting of the chemicals and biological materials used in tests to detect the presence of pathogen-specific markers. These include primers, probes, antibodies, and enzymes necessary for assays. The need for reagents is sustained by the volume of tests performed and the diversity of pathogens that can be tested. Hence, laboratories often prefer vendors who can provide various reagents compatible with multiple instrument platforms. The software segment in infectious disease diagnostics includes data analysis, interpretation software, and information management systems that are critical for the operational efficiency of diagnostics. Preferences in software are based on user-friendly interfaces, robust data management capabilities, interoperability with other hospital systems, and compliance with regulatory standards such as HIPAA.

Technology: Expanding adoption of molecular diagnostics technology to quickly detect and quantify viral load, such as in HIV or hepatitis infections

Immunochemistry, or immunoassay, is a key technology in infectious disease diagnostics, using the immune response (antibodies, antigens) to detect and quantify specific biomarkers in a sample. It includes tests such as ELISA (enzyme-linked immunosorbent assay), lateral flow assays, and Western blotting. Microbiology remains a foundational method for identifying infectious diseases, often involving collecting samples to isolate and identify pathogens using biochemical and phenotypic analysis. Microbiology is essential for drug resistance testing and understanding the epidemiology of infections. It's preferred when information about the antibiotic susceptibility of pathogens is required, guiding targeted treatment. Molecular diagnostics involves analyzing nucleic acids to identify infectious agents with high sensitivity and specificity. Common technologies include polymerase chain reaction, reverse-transcription PCR, and next-generation sequencing.

Regional Insights

The Americas represents a significant portion of the infectious diseases in-vitro diagnostics market due to its advanced healthcare infrastructure, high prevalence of infectious diseases, and strong presence of leading market players. Recent trends include the adoption of Molecular Diagnostics (MDx), Point-of-Care (PoC) testing, and increased investment in personalized medicine. EU countries exhibit diverse healthcare systems and regulations but collectively show a strong demand for high-quality in-vitro diagnostics. EU customers value the precision and reliability of tests, combined with the need for compliance with stringent EU regulations. The Middle East and Africa region encompass various markets with varying degrees of development. In Middle Eastern countries, there is a significant demand for state-of-the-art healthcare solutions, including the latest in-vitro diagnostics. Investments in healthcare infrastructure are notable in the Gulf Cooperation Council (GCC) countries. Meanwhile, the African market needs cost-effective and robust testing due to challenges like infectious disease prevalence and limited access to healthcare. International initiatives often drive investment and innovation, focusing on expanding access and building local expertise in diagnostics.

The Asia Pacific region is rapidly growing in the infectious diseases in-vitro diagnostics market. China's vast population and increasing healthcare expenditures drive market growth, with strong government support for improving healthcare infrastructure. Japan, with its advanced technology, focuses on high-end, automated diagnostic solutions and is an innovation hub with significant patents in diagnostics technology. India's market is burgeoning due to rising awareness and affordability. Preventive screenings and accessibility to diagnostics have become pivotal in customer purchasing behavior across the Asia Pacific region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Infectious Diseases In-Vitro Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Infectious Diseases In-Vitro Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Infectious Diseases In-Vitro Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Danaher Corporation, DiaSorin S.p.A, DX Lab Inc., Epitope Diagnostics, Inc., F. Hoffmann La-Roche Ltd., Genspeed Biotech GmbH, Grifols, S.A., Hologic, Inc., Illumina, Inc., InBios International, Inc., Koninklijke Philips N.V., Laboratory Corporation Of America Holdings, Merck KGaA, Meril Life Sciences Pvt. Ltd., OraSure Technologies, Inc., PerkinElmer, Inc., Qiagen N.V., Quest Diagnostics, Quidel Corporation, Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific Inc., Trinity Biotech PLC, Uniogen Oy, and Vela Diagnostics.

Market Segmentation & Coverage

This research report categorizes the Infectious Diseases In-Vitro Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
  • Instruments
  • Reagents
  • Software

• Technology
  • Immunochemistry
  • Microbiology
  • Molecular Diagnostics

• Indication
  • Candidiasis
  • Chlamydia
  • Clostridium difficile
  • CRE
  • Gastroenteritis
  • Gonorrhea
  • Hepatitis
  • HIV
  • HPV
  • MRSA
  • Respiratory Virus
  • Streptococcus
  • TB and Drug-resistant TB
  • VRE

• End-user
  • Academic Research Institutes
  • Diagnostic Laboratories
  • Hospitals & Clinics

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Infectious Diseases In-Vitro Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Infectious Diseases In-Vitro Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Infectious Diseases In-Vitro Diagnostics Market?

4. What is the market share of the leading vendors in the Infectious Diseases In-Vitro Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Infectious Diseases In-Vitro Diagnostics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing Prevalence and Periodic Outbreak of Infectious Diseases
    • 5.1.1.2. Rising Adoption of Rapid Test Kits for Diagnosis of Infectious Diseases
    • 5.1.1.3. Implementation of Government Initiatives to Curb Viral Diseases
  • 5.1.2. Restraints
    • 5.1.2.1. Product Recalls of Infectious Disease In-vitro Diagnostics
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in Genomics and Proteomics
    • 5.1.3.2. Increasing Investments in R&D to Launch New IVD Products
  • 5.1.4. Challenges
    • 5.1.4.1. Limited Accessibility of Infectious Diseases In-vitro Diagnostics Kits
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Rising demand for advanced reagents for testing infectious pathogens
  • 5.2.2. Technology: Expanding adoption of molecular diagnostics technology to quickly detect and quantify viral load, such as in HIV or hepatitis infections
• 5.3. Market Trend Analysis
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework Analysis
• 5.9. Client Customization

6. Infectious Diseases In-Vitro Diagnostics Market, by Product

• 6.1. Introduction
• 6.2. Instruments
• 6.3. Reagents
• 6.4. Software

7. Infectious Diseases In-Vitro Diagnostics Market, by Technology

• 7.1. Introduction
• 7.2. Immunochemistry
• 7.3. Microbiology
• 7.4. Molecular Diagnostics

8. Infectious Diseases In-Vitro Diagnostics Market, by Indication

• 8.1. Introduction
• 8.2. Candidiasis
• 8.3. Chlamydia
• 8.4. Clostridium difficile
• 8.5. CRE
• 8.6. Gastroenteritis
• 8.7. Gonorrhea
• 8.8. Hepatitis
• 8.9. HIV
• 8.10. HPV
• 8.11. MRSA
• 8.12. Respiratory Virus
• 8.13. Streptococcus
• 8.14. TB and Drug-resistant TB
• 8.15. VRE

9. Infectious Diseases In-Vitro Diagnostics Market, by End-user

• 9.1. Introduction
• 9.2. Academic Research Institutes
• 9.3. Diagnostic Laboratories
• 9.4. Hospitals & Clinics

10. Americas Infectious Diseases In-Vitro Diagnostics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Infectious Diseases In-Vitro Diagnostics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Infectious Diseases In-Vitro Diagnostics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Roche Launches Next-Generation Qpcr System to Advance Clinical Needs In Molecular Diagnostics and Address Public Health Challenges
  • 13.3.2. Biocare Medical Announces the Launch of ARC: The New IVD Antigen Retrieval Chamber for Reliable, Precise and Consistent Heat Induced Epitope Retrieval (HIER)
  • 13.3.3. Launch of Optimer-Fc as a New Reagent Solution for Immunohistochemistry
  • 13.3.4. DxLab Delivers Lab-Quality Detection of Infectious Diseases and Harmful Pathogens in a Toaster-Size Box

14. Competitive Portfolio

• 14.1. Key Company Profiles
• 14.2. Key Product Portfolio